Ariela Katz

Articles

Leonard Highlights Agents, Approaches in Pipeline for Hematologic Malignancies

May 10th 2017

John P. Leonard, MD, discusses advancements across hematologic malignancies and pivotal trial data he is anticipating at the 2017 ASCO Annual Meeting.

Novel Imaging Agent May Improve Prostate Cancer Detection

May 2nd 2017

An investigational radiotracer that targets prostate-specific membrane antigen is being tested in patients with high-risk, recurrent, or metastatic prostate cancer to determine whether the novel agent can improve upon the sensitivity and specificity of conventional imaging.

ASCO Issues Guidance on Second-Line Treatment of CRPC

April 25th 2017

Informed by new clinical evidence, ASCO has issued updated guidance on the use of second-line hormonal therapy for chemotherapy-naïve patients with castration-resistant prostate cancer.

Next-Generation Therapies in CRPC Take Aim at AR Resistance

April 19th 2017

As a wealth of research has shown in the past several years, therapies that target the androgen receptor pathway in patients with castration-resistant prostate cancer encounter complex mechanisms of resistance including the likelihood that more than 1 such signaling network is active in each individual.

Novel Drug Targets Cancer Stem Cell Pathway in Metastatic CRC Trial

April 17th 2017

The international CanStem303C trial is evaluating the combination of napabucasin, the most advanced cancer stemness inhibitor in development, with FOLFIRI chemotherapy in patients with previously treated metastatic colorectal cancer.

Liquid Biopsy Testing Detects Recurrence in High-Risk NSCLC

April 13th 2017

The results of a recent prospective study demonstrate that circulating tumor cells can reveal disease recurrence an average of 6 months prior to conventional imaging in patients with locally advanced non–small cell lung cancer, findings that may help support the use of liquid biopsies to monitor high-risk patients in conjunction with screening.

Novel HER2 Inhibitor May Help Treat Brain Tumors in Breast Cancer Patients

April 7th 2017

Investigators are seeking to determine whether adding tucatinib (ONT-380), a novel small-molecule HER2 inhibitor, to standard therapies will improve outcomes for patients with progressive metastatic HER2-positive breast cancer, including those with brain tumors.

Next-Generation Sequencing Company Sets Sights on $100 Genome Analysis

March 21st 2017

The NovaSeq 5000 and the NovaSeq 6000, from Illumina, are series sequencers designed to conduct large-scale genomics projects with greater sample volumes, which lowers the per-sample costs for most applications.

Evidence Builds for Targeting PD-1/PD-L1 Pathway in Bladder Cancer

March 21st 2017

As the number of tumor types with approved PD-1/PD-L1 pathway inhibitors continues to expand, bladder cancer has become a robust area of development.

Innovative Immunotherapy Combo Tests IDO Inhibitor in Melanoma Trial

March 20th 2017

Investigators are looking into a novel immunotherapy combination that pairs the first-in-class IDO1 inhibitor epacadostat (INCB024360) with the checkpoint blockade agent pembrolizumab (Keytruda) in patients with unresectable or metastatic melanoma.

Antibody-Drug Conjugate Under Study in Platinum-Resistant Ovarian Cancer

February 28th 2017

A novel targeted therapy, mirvetuximab soravtansine (IMGN853), is being investigated as a single-agent treatment for patients with advanced, platinum-resistant epithelial ovarian cancer with medium and high expression levels of folate receptor-alpha in an effort to provide an effective option for a population facing a difficult prognosis.

Biomarker-Driven Study Aims for Genomic Breakthroughs in AML

February 24th 2017

A wide-ranging clinical trial is investigating a novel method of determining treatment regimens for acute myeloid leukemia based on genomic testing for each individual patient.

Lancaster Urology Brings Clinical Trials to Community Setting

February 21st 2017

Lancaster Urology, one of the largest urology practices in western Pennsylvania, fills the geographic void between Pittsburgh and Philadelphia by providing the whole spectrum of urologic care.

First SITC Guidelines in RCC Address Continuing Role of Interleukin-2 and Emergence of Nivolumab

February 21st 2017

New guidelines involving the immunotherapies nivolumab (Opdivo) and interleukin-2 inhibitors have been issued by The Society for Immunotherapy of Cancer to help practicing clinicians manage patients with renal cell carcinoma.

Assays Break New Ground in Oncology

February 16th 2017

Two novel imaging agents and 6 clinical assays for use in cancer care gained the FDA's approval in 2016, marking advances in the diagnostic field.

Veliparib Facing Phase III Test in BRCA-Positive Breast Cancer

January 12th 2017

Researchers are seeking to determine whether adding the PARP inhibitor veliparib to a chemotherapy combination will improve outcomes for patients with HER2-negative, germline BRCA-associated metastatic or locally advanced breast cancer.

The Future of Biomarkers in Prostate Cancer

January 6th 2017

At this year’s Chemotherapy Symposium held in New York, a standout presentation by Mark Stein, MD, showed that there is a lot of promise in the area of circulating tumor cell biomarkers for patients with prostate cancer.

Novel Interleukin-Based Immunotherapy Under Study in Pancreatic Cancer

December 29th 2016

An immunotherapy combination that adds the interleukin-10 agonist AM0010 to FOLFOX chemotherapy will be evaluated in a phase III trial for patients with metastatic pancreatic cancer that could introduce a new modality to the treatment paradigm for the malignancy.

Sanofi's Halt of BCG Production Worries Bladder Cancer Patients and Urologists

December 1st 2016

Sanofi Pasteur plans to discontinue production of Bacillus Calmette-Guérin for the US market by mid-2017, startling physicians and patients who fear that a shortage of the widely used bladder cancer therapy will develop.